BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 31715421)

  • 1. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
    J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET fusion gene: translation to personalized lung cancer therapy.
    Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
    Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: identification of
    Ma J; Wang B; Meng E; Meng X
    Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting RET alterations in non-small cell lung cancer.
    Nishikawa G; Klein MA
    Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.